

**CORPORATE OFFICE :**  
1st floor, 137 Hubtown Solaris,  
N.S. Phadke Road, Opp. Teli Galli,  
Near Andheri East West Flyover Bridge.  
Andheri East. Mumbai - 400069 (INDIA).  
CIN No. L24232MP1989PLC005390  
Tel. : 91-22-6863 4200 / 6863 4206  
Fax : (91) 022-2206 3929  
E-mail : poltd@panchsheelorganics.in  
Website : <http://www.panchsheelorganics.com>



**Panchsheel  
Organics  
Limited**  
MFGRS. OF: BULK DRUGS  
& FORMULATIONS

November 19, 2023

To,  
BSE Limited,  
P. J. Tower, Dalal Street,  
Fort, Mumbai - 400 001.

Dear Sirs,

**Scrip Code: 531726**

**Sub: Earnings Release & Shareholder's Letter**

Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), we enclose herewith Earnings Release & Shareholder's Letter of the company.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**For Panchsheel Organics Limited**

MAHENDRA  
ABHAYCHAND  
TURAKHIA

Digitally signed by MAHENDRA  
ABHAYCHAND TURAKHIA  
Date: 2023.11.19 11:31:38 +05'30'

**Mahendra A. Turakhia**  
**Managing Director**  
**DIN: 000062**



# EARNINGS RELEASE & SHAREHOLDERS' LETTER

Q2 & H1 FY24 | November 16, 2023



## About us:

- Panchsheel Organics Limited is an India-based company engaged in the manufacturing and exporting of active pharmaceutical ingredients (APIs), intermediates and finished formulations. The company was founded in 1990 by the Turakhia Bros Group, which has a 35-year track record in the pharma industry.
- The company has established itself as a prominent player in the manufacturing of Active Pharmaceutical Ingredients (APIs) with its state-of-the-art manufacturing plant and a strong R&D setup located in Indore, Madhya Pradesh.
- The facilities are equipped with machinery and technology to produce high-quality APIs which comply with all norms applicable as per GMP & WHO standards. The company is also ISO 9001:2008 certificated Further, the company has strong presence globally and exports to more than 15 countries.
- Company boasts product portfolio, encompassing a range of pharmaceuticals including Carbamazepine IP, Irbesartan BP, Eslicarbazepine Acetate IP, Nitrofurantoin (Hydrous) USP, and Oxcarbazepine IP, etc.
- Panchsheel Organics' impressive client portfolio, which includes leading domestic manufacturers and MNCs like Zydus, Abbott, Swiss Garnier, and Ajanta Pharma, etc. underscores its strong market presence and reliability as a strategic partner.

## Product Category:

### Active Pharmaceutical Ingredients (APIs) (Current Product Profile)

**Nitrofurantoin IP (Anhydrous)**

**Rutin (Rutoside Trihydrate BP)**

**Nitrofurantoin (Hydrous) USP**

**Eslicarbazepine Acetate IP**

**Dobutamine HCL USP**

**Carbamazepine IP**

**Oxcarbazepine IP**

**Carbocisteine BP**

**Irbesartan BP**

**Carvedilol IP**

### Fermentation (Future Product Profile)

**Probiotics**





**Antibiotics**

**Anti Cancer**

**Enzymes**

**API**

# Key Financial Matrix:



# Consolidated Income Statement:

Particulars (Rs. Mn)	Q2 FY24	Q2 FY23	Y-o-Y	Q1 FY24	H1 FY24	H1 FY23	Y-o-Y
Revenue from Operations	237.06	243.33	(2.58)%	246.30	483.36	456.89	5.79%
Other Income	10.09	0.03		1.04	11.12	0.05	
<b>Total Revenue</b>	<b>247.15</b>	<b>243.35</b>		<b>247.34</b>	<b>494.48</b>	<b>456.95</b>	
Total Expenses excl. D&A & Finance Cost	192.77	190.27		197.58	390.36	353.54	
<b>EBITDA</b>	<b>44.29</b>	<b>53.05</b>	(16.52)%	<b>48.72</b>	<b>93.01</b>	<b>103.35</b>	(10.01)%
<b>EBITDA Margin (%)</b>	<b>18.68%</b>	<b>21.80%</b>		<b>19.78%</b>	<b>19.24%</b>	<b>22.62%</b>	
Finance Cost	1.06	0.87		0.67	1.73	1.36	
Depreciation & Amortization	4.05	3.12		3.84	7.89	6.35	
PBT	49.26	49.10		45.25	94.51	95.69	
Tax	12.40	12.36		11.39	23.79	24.08	
<b>PAT</b>	<b>36.86</b>	<b>36.74</b>	0.32%	<b>33.86</b>	<b>70.72</b>	<b>71.61</b>	(1.24)%
<b>PAT Margin %</b>	<b>15.55%</b>	<b>15.10%</b>		<b>13.75%</b>	<b>14.63%</b>	<b>15.67%</b>	
Other comprehensive profit/loss	0.21	0.30		0.21	0.43	0.60	
<b>Net PAT</b>	<b>37.07</b>	<b>37.04</b>		<b>34.07</b>	<b>71.15</b>	<b>72.21</b>	
<b>Diluted EPS</b>	<b>2.47</b>	<b>3.41</b>		<b>2.59</b>	<b>4.74</b>	<b>3.41</b>	

# Consolidated Balance Sheet:

Particulars (Rs. Mn)	As on 30.09.23	As on 31.03.23
<b>Assets</b>		
<b>Non-current assets</b>		
Property, plant and equipment	82.14	76.92
Capital WIP	42.10	35.30
Financial Assets		
-Non current investments	30.01	0.01
-Loans	-	-
-Other Financial Assets	332.76	321.19
Def Tax Assets (Net)	3.59	3.59
Other non-current assets	28.06	28.06
<b>Total non-current assets</b>	<b>518.66</b>	<b>465.07</b>
Inventories	363.68	324.42
Trade Receivables	414.90	387.90
Cash & Cash Equivalents	62.70	37.09
Other Current Assets	12.48	10.17
Short Term loan and advances	2.31	2.19
<b>Total current assets</b>	<b>856.08</b>	<b>761.77</b>
<b>TOTAL ASSETS</b>	<b>1,374.73</b>	<b>1,226.83</b>

Particulars (Rs. Mn)	As on 30.09.23	As on 31.03.23
<b>Equity &amp; liabilities</b>		
<b>Equity</b>		
Equity share capital	117.82	117.82
Other equity	904.54	842.81
<b>Total equity</b>	<b>1,022.35</b>	<b>960.63</b>
Financial Liabilities		
-Borrowings	4.16	5.40
-Trade Payables	-	5.67
Employee Benefit Obligations	11.94	12.22
Other Non -Current Liabilities	6.09	6.09
<b>Total non-current liabilities</b>	<b>22.19</b>	<b>29.38</b>
Financial Liabilities		
-Borrowings	53.28	50.39
-Trade Payables	244.82	158.82
-Other Financial Liabilities	8.05	9.37
Income tax liabilities (net)	15.37	7.18
Employee Benefit Obligations	7.08	5.24
Other Current liabilities	1.59	5.83
<b>Total current liabilities</b>	<b>330.19</b>	<b>236.82</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>1,374.73</b>	<b>1,226.83</b>

## Notable Updates during Q2 FY24:

- Company is happy to declare Interim Dividend of Rs. 0.80 per share and record date for dividend is 04th December 2023

## Capex Update:

Panchsheel Organics Limited is making substantial progress towards the launch of their advanced fermentation plant in Q1 FY25, having completed 50% of the necessary construction work on schedule. They have already initiated the procurement of machinery and equipment, focusing on efficient installation and commissioning over the next 6-8 months, demonstrating their commitment to maintaining operational excellence and product quality.

## Management Commentary:

***Commenting on the performance of Q2 FY24, the management team of Panchsheel Organics Ltd. stated:***

*“It gives me immense pleasure to introduce Panchsheel Organics Ltd., a company engaged in manufacturing and trading of APIs, Intermediates and Formulations. The Company has rich experience of over 35 years in developing specialty molecules in the space of Antibacterial, Anticonvulsants, Autism and many more backed by its strong R&D and indigenous manufacturing capabilities.*

*Our R&D team has constantly enforced strict controls to uphold and sustain our high standards, which has helped the business broaden its product offering and client base. Further, we have a state-of-the-art API manufacturing facility situated in Indore, Madhya Pradesh spanning across 7,500 sq. mt. of land, accommodating four manufacturing blocks that cover an area of 5,000 sq. mt. With ~35 years in the industry, we have cultivated a reputed clientele comprising of companies like Abbott, Ajanta Pharma, Zydus, etc. and also have our footprints in the international markets.*

*On the financial front, our revenue from operations was ₹237.06 Mn in Q2 FY24. EBITDA remained stable at ₹44.29 Mn margins remained constant at 18.68%. PAT increased from ₹36.74 Mn in Q2 FY23 to ₹36.86 Mn in Q2 FY24 while PAT margins increased from 15.10% to 15.55% during the same period.*

*We are excited to announce that Panchsheel Organics Limited is making significant progress towards the commencement of our first state-of-the-art fermentation plant, scheduled for Q1 FY25. As of now, we have successfully completed 50% of the civil work required for the plant's construction. This marks a crucial milestone in our expansion strategy, reinforcing our commitment to meeting the increasing demand for our products. The plant's construction progress is on schedule, and we are confident in our ability to execute this project efficiently.*

*To ensure operational readiness, we have already placed orders for the necessary machinery and equipment. Over the next 6-8 months, we will focus on the installation and commissioning of these machines. This phased approach aligns with our commitment to maintaining high levels of operational efficiency and product quality. Once operationalize, the fermentation plant will have applications in Enzymes, Pro - biotics, Anti Cancer, etc. and significantly enhance our production capacity, enabling us to tap into new markets and revenue streams. We are optimistic that this expansion will contribute positively to our financial performance and long-term stakeholder value.*

*We would like to thank our employees for their continuous efforts, as well as our investors/stakeholders for their encouragement and support as we go forward in capturing the growth opportunities that lie ahead of us."*

---

## **Disclaimer:**

*Certain statements in this document may be forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Panchsheel Organics Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstance*

## **Contact Details:**

**Mahendra Turakhia (Chairman & MD)**

**Panchsheel Organics Limited**

**Contact: +91 9009561786**

**Email: poltd@panchsheelorganics.in**

**Vinayak Shirodkar/Naman Maheshwari**

**Captive IR Strategic Advisors Pvt. Ltd.**

**Contact: +919372467194**

**Email: vinayak@cap-ir.com/naman@cap-ir.com**